Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy.
about
Medium-term outcome of recipients of marginal donor hearts selected with new stress-echocardiographic techniques over standard criteriaConnective tissue growth factor promotes fibrosis downstream of TGFbeta and IL-6 in chronic cardiac allograft rejection.Assessment of sub-clinical acute cellular rejection after heart transplantation: comparison of cardiac magnetic resonance imaging and endomyocardial biopsy.Value of the first post-transplant biopsy for predicting long-term cardiac allograft vasculopathy (CAV) and graft failure in heart transplant patientsEarly inflammatory markers are independent predictors of cardiac allograft vasculopathy in heart-transplant recipients.Anticardiac myosin immunity and chronic allograft vasculopathy in heart transplant recipients.Cardiac retransplantation is an efficacious therapy for primary cardiac allograft failure.A novel pathway of chronic allograft rejection mediated by NK cells and alloantibodyInduction of vascular atrophy as a novel approach to treating restenosis. A reviewCardiac allograft vasculopathy and insulin resistance--hope for new therapeutic targetsTim-1-Fc suppresses chronic cardiac allograft rejection and vasculopathy by reducing IL-17 productionRecipient-derived EDA fibronectin promotes cardiac allograft fibrosis.TGF-beta, IL-6, IL-17 and CTGF direct multiple pathologies of chronic cardiac allograft rejection.Mechanism of arterial remodeling in chronic allograft vasculopathy.The presentation and diagnosis of coronary allograft vasculopathy in pediatric heart transplant recipients.Role of regulatory T cells in the promotion of transplant tolerance.Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms.Interacting mechanisms in the pathogenesis of cardiac allograft vasculopathy.Extracorporeal photopheresis after heart transplantation.Current diagnostic and treatment strategies for cardiac allograft vasculopathy.Novel therapeutic and diagnostic management of heart transplant patients.The CECARI Study: Everolimus (Certican®) Initiation and Calcineurin Inhibitor Withdrawal in Maintenance Heart Transplant Recipients with Renal Insufficiency: A Multicenter, Randomized Trial.Outcome after heart transplantation from older donor age: expanding the donor pool.Elevated serum uric acid levels following heart transplantation predict all-cause and cardiac mortality.Off-pump coronary artery bypass grafting for a left main lesion due to cardiac allograft vasculopathy in Japan: first report of a case.Advancing immunosuppression in heart transplantation: "one step forward, two steps back.Adherence to Mediterranean and low-fat diets among heart and lung transplant recipients: a randomized feasibility study.Outcomes and survival following heart retransplantation for cardiac allograft failure: a systematic review and meta-analysis.SDF-1/CXCR4/CXCR7 is pivotal for vascular smooth muscle cell proliferation and chronic allograft vasculopathy.The Cardiac Allograft Is Going Up in Smoke: A Call to Action
P2860
Q33800446-7995AA8B-537A-4211-90DD-8C574B9A8D22Q33811918-AF3C5D51-8329-40C3-B9F3-C44467C79264Q34136559-D7C607EE-9ACB-4053-A78E-62043CFF9995Q34257142-951B6B1D-6E93-4719-9463-FB3F0BF8B665Q34662795-279FB113-5BAF-40C3-B8A7-2D14C5F6220CQ35091339-9796FB07-42A6-4CDE-BC09-D6C907A08A14Q36728769-2F8E530B-6131-4F04-8B87-86586D0814E3Q36887068-1259D868-A595-4CDE-887E-B9649647C640Q36976632-B4F11675-8BA7-432A-B4DC-5BA77CA1B3ADQ36993722-3C5C286E-3099-475A-A103-3DAFF23FBB11Q37587334-8ACC08C1-8158-4F03-BE94-613CDD1525ACQ37709678-B247371C-E43F-469A-8E8E-E9C951331809Q37773292-C221F664-86D0-4936-A3BD-4E4F94B8787BQ37941478-9E67E34C-E120-4675-A6C3-3224A3492A55Q38002150-1BE941D6-172A-4704-A152-C2521CD2E3AEQ38004403-F4DACDB3-EA83-40DF-9975-36779CE441DBQ38061056-EF6D5D56-B093-4ACE-A521-330D745E989FQ38218005-33D09949-0FFD-4BA8-9D76-8A367E223C55Q38260052-9EC3E94F-B982-4C59-8BC7-64AD06E24900Q38592122-E3BBCB40-9378-41D3-AA5C-B883D8085848Q38614686-EAA1E7C1-2391-4077-8E64-3BEB126F4E61Q41847223-93D6E92E-E870-4DBF-9E2A-FA20897E0CEBQ43426990-656716D4-13C5-42D2-82F0-C55384455037Q44924891-FC139E47-6BCA-4D1B-A26F-6A4E542CF190Q45222416-1B5FD3A3-FE93-4F0A-A830-22479EDC27A4Q46295855-B686B0BF-9E38-4C4D-BA7C-F8423CB661FFQ49996766-C1404408-157B-45B3-A928-4E69625067A9Q52680428-CA4B74AC-24A1-40B9-A287-EFEE9CDAC1B3Q52863308-6292929A-219C-44C0-B9E4-47D3CF55853DQ57652824-651A39A1-0383-4061-BE3B-D0633B5A675E
P2860
Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy.
@ast
Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy.
@en
type
label
Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy.
@ast
Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy.
@en
prefLabel
Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy.
@ast
Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy.
@en
P2860
P1476
Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy.
@en
P2093
P2860
P304
P356
10.1111/J.1600-6143.2006.01314.X
P407
P577
2006-06-01T00:00:00Z